The world of Kedrion Biopharma at a glance:
discover the latest
up-to-date news.

All news.
Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Announced appointment of Ugo Di Francesco as CEO
Read all
Kedrion Biopharma Recognized for Innovation in Treating Rare Disease
RYPLAZIM® is the first FDA Approved Treatment for Plasminogen Deficiency Type 1
Read all
Kedrion Biopharma Extends Contract Manufacturing Agreement (CMA) for GAMMAKED in the US, Ensuring Availability to Patients
Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025
Read all